EEC News and Events
Find out more about EEC news and events and related meetings from other organisations.
EEC Network Meetings in 2026
Tuesday 20 January 2026 (online meeting)
Join us for an update on progress in Ewing sarcoma research with presentations from experts from Europe and the USA. The meeting will be on Zoom, link to be sent by 13th January 2026. Register today.
We have opportunities for early-career researchers to present their work. If you would like to apply, please complete this form by Sunday 23 November 2025. Fill out form.
Download the full agenda below:
Monday 29 and Tuesday 30 June 2026 (hybrid meeting)
Venue: Friends House, London.
Registration will open in March 2026.
Publication of analysis of data from EE99 and EWING-2008 trials
The paper “Impact of age on safety of Busulfan-Melphalan followed by autologous hematopoietic stem-cell transplantation versus standard chemotherapy in the patients of the EURO-E.W.I.N.G. 99 and Ewing 2008 clinical trials” has been published in the European Journal of Cancer.
This arm of the EE99 and Ewing-2008 trials compared VIDE induction therapy in unfavourable localised ES followed by either high-dose chemotherapy (Busulfan-Melphalan) and autologous hematopoietic stem cell transplantation or conventional chemotherapy (vincristine-dactinomycin-ifosfamide - VAI) and evaluated the risk of acute toxicity in each group within different age groups.
The authors conclude that “The excess of acute toxicity associated with BuMel compared to VAI does not vary significantly with age, suggesting the feasibility of BuMel across all age groups.” The EE99 and Ewing-2008 trial were both closed by the end of 2015. Since then, the Euro Ewing 2012 trial has demonstrated that VDC-IE induction therapy, rather than VIDE, should be the standard of care for all newly-diagnosed ES patients.
